Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is used to improve muscle strength in patients with myasthenia gravis and to aid recovery of bowel motility after surgery. GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon acts on the neuromuscular junction to increase acetylcholine availability, benefiting conditions characterized by muscle weakness or impaired gastrointestinal motility.

Myasthenia gravis: improves skeletal muscle strength and reduces fatigue. Postoperative ileus: promotes return of normal bowel movements after abdominal surgery. Ocular myasthenia: lessens eye‑muscle fatigue and improves visual function.

Mestinon may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal cramps - Increased salivation or sweating - Muscle cramps or fasciculations - Dizziness or headache - Excessive sweating

Serious or Rare Side Effects: - Cholinergic crisis with respiratory distress - Severe bradycardia or heart block - Bronchospasm or severe airway obstruction - Seizures or convulsions - Anaphylactic reaction or severe skin rash - Persistent muscle weakness despite therapy

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: adjust dose based on renal function. - Asthma or COPD: monitor for bronchospasm. - Concomitant anticholinergic drugs: may reduce efficacy. - Signs of cholinergic excess: educate patients to report muscle twitching or excessive sweating. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Pyridostigmine bromide can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Other cholinesterase inhibitors: additive cholinergic effects. - Anticholinergic agents (e.g., atropine, antihistamines): antagonize therapeutic action. - Aminoglycoside antibiotics: potentiate neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may exacerbate bradycardia. - Diuretics: risk of electrolyte imbalance. - Anesthetic agents (e.g., succinylcholine): increased sensitivity. - NSAIDs: possible gastrointestinal irritation. - Thyroid hormones: may alter drug metabolism.